The facts
Profluent at a glance.
Read Oct 20, 2026. Valuations and amounts are copied as each source states them; a figure that is only reported (talks, or people familiar with the deal) is labeled as reported.
- Kind of company
- Drug discovery and biologyAI that designs drugs, proteins and antibodies.
- Based in
- Emeryville, California, United States
- Founded
- 2022Business Wire (Profluent press release), Sep 30, 2026
- Last closed-round valuation
- nearly $1Bapproaching $1 billion (Forbes, Amy Feldman, Nov 19, 2025)
- What it has shipped
- Has a model or API
Founders
- Ali Madani: AI researcher with a UC Berkeley doctorate; worked at Salesforce, where the ProGen project launched; lead author of a Nature Biotechnology paper on ProGen (Forbes, Amy Feldman, Nov 19, 2025)
- Alexander Meeske: University of Washington lab head (Forbes says he teamed up with Madani to build the company) (Forbes, Amy Feldman, Nov 19, 2025)
Partnership with BioMarin on AI-designed enzyme therapies (financial terms not disclosed). Sep 30, 2026
Business Wire (Profluent press release), Sep 30, 2026
What it has built
Shipped, or not yet.
“Has a model or API” is what our search found: something the public can use or buy, a model or API, research only, or nothing public.
1 round
Funding, as reported.
Every round we found, with the amount, valuation and investors as the source states them.
| When | Round | Amount | Valuation | Investors named | Source |
|---|---|---|---|---|---|
| Nov 19, 2025 | Not specified | $106 million (total raised $150 million) | approaching $1 billion | Bezos Expeditions (co-lead), Altimeter Capital (co-lead) | Forbes, Amy Feldman |
Our note
Worth knowing.
Our note: A Bloomberg headline reposted by Profluent (2026-04-28) says a Lilly deal is worth up to $2.25 billion; the Bloomberg article itself could not be fetched, so terms are unverified. OpenCRISPR-1 results are from a preprint; no peer-reviewed version was found on pages fetched. No own clinical pipeline found.
More drug discovery and biology